Skybound develops platform medical technologies that counter the rapid physiological decline humans experience in space, aiming to sustain long‑duration missions. By targeting barriers such as bone loss, muscle atrophy, neuro‑ocular syndrome, immune dysregulation, and radiation‑induced genomic injury, its solutions also address age‑related decline and chronic disease on Earth, enabling autonomous, personalized healthcare.
Funding
Funding not disclosed
Founders
Product
Problem
Long-duration spaceflight causes rapid physiological decline—including bone loss, muscle atrophy, neuro‑ocular syndrome, immune dysregulation, and radiation‑induced genomic damage—making sustained human presence in orbit or beyond unviable.
Solution
Skybound creates platform medical technologies that directly counter the key physiological barriers encountered in space. By developing interventions that preserve musculoskeletal integrity, support immune function, protect genomic stability, and mitigate neuro‑ocular effects, the company aims to maintain astronaut health during extended missions. These platform solutions are designed to be adaptable, enabling both autonomous in‑flight treatment and integration with Earth‑based medical protocols. The same technologies are leveraged to address age‑related chronic diseases on Earth, creating a dual‑use pathway that accelerates development and commercial viability. Skybound’s innovation engine follows a systematic process: identify severe space‑induced barriers, then build scalable platform therapies that can be personalized to individual physiological needs.
Target Audience
Primary customers are national space agencies, commercial spaceflight operators, and aerospace research organizations developing long‑duration crewed missions, as well as biomedical firms and healthcare providers focused on aging and chronic disease therapeutics.
Features
- Platform therapies targeting disuse osteopenia and sarcopenia to maintain bone density and muscle mass under microgravity conditions
- Immune‑modulating agents that prevent T‑cell dysfunction and latent viral reactivation during prolonged missions
- Countermeasures for Spaceflight‑Associated Neuro‑ocular Syndrome, protecting ocular pressure and optic nerve health
- Radioprotective technologies that reduce high‑LET DNA damage and lower long‑term carcinogenic risk from cosmic radiation
- Modular, self‑sustaining delivery systems designed for autonomous operation with minimal clinician oversight
- Adaptable formulations that can be repurposed for age‑related musculoskeletal, immune, and genomic disorders on Earth